Related Experiment Video
Updated: Jul 12, 2026
11:53
Spatial Multiobjective Optimization of Agricultural Conservation Practices using a SWAT Model and an Evolutionary Algorithm
Published on: December 9, 2012
Strategic planning for applied pharmacoeconomics programs
Pharmacy Practice Management Quarterly
|December 9, 1995
Summary
Rising healthcare costs necessitate demonstrating value in drug therapy. Pharmacoeconomics programs, like those at M.D. Anderson and Oregon Health Sciences University, ensure optimal outcomes for pharmaceutical spending.
Area of Science:
- Health economics
- Pharmaceutical policy
- Healthcare management
Background:
- Healthcare costs are escalating, impacting service delivery infrastructure.
- Managed care and national health plans aim to control rising drug therapy expenses.
- Demonstrating value for money is crucial amid increasing demand and shrinking resources.
Purpose of the Study:
- To present pharmacoeconomics as a mechanism for establishing the value of drug therapy.
- To illustrate the development of applied pharmacoeconomics programs in healthcare settings.
- To showcase case studies from M.D. Anderson Cancer Center and Oregon Health Sciences University.
Main Methods:
- Strategic planning process utilized for program development.
- Case study approach examining two distinct healthcare institutions.
- Focus on integrating pharmacoeconomics into pharmaceutical services.
Main Results:
- Successful development of pharmacoeconomics programs in leading cancer and university hospitals.
- Programs established to ensure optimal outcomes from drug therapy expenditures.
- Defined activities essential for an applied pharmacoeconomics program.
Conclusions:
- Pharmacoeconomics is vital for demonstrating the value of drug therapy in cost-constrained environments.
- Applied pharmacoeconomics programs can be developed using strategic planning.
- These programs ensure efficient allocation of resources for pharmaceutical services and drug therapy.
More Related Videos
05:10Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
01:20Pharmacokinetic Models: Overview
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:26Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).